439691-80-2

Basic information

• Product Name: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE
• Synonyms: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE;1-(3-Formylbenzyl)-4-methylpiperazine;4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde 97%;1-(4-Formylbenzyl)-4-methylpiperazine
• CAS NO: 439691-80-2
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 218.29
• Mol File: 439691-80-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 338.9 °C at 760 mmHg
• Flash Point: 141.3 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 9.53E-05mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(439691-80-2)
• EPA Substance Registry System: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(439691-80-2)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 439691-80-2(Hazardous Substances Data)

Usage

General Description

4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde is a chemical compound that features a benzaldehyde group, which is a type of aromatic aldehyde, attached to a methylpiperazine group. It's relatively complex structure suggests potential use in several fields, but specifics might depend on its physical and chemical properties. 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE is not widely discussed or studied in existing literature, indicating it may not be widely used or may be used under different names or within mixtures. The potential hazards, toxicity and ecological impact of 4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde are also largely unknown, potentially due to lack of extensive research on this specific compound.

InChI:InChI=1/C13H18N2O/c1-14-6-8-15(9-7-14)10-12-2-4-13(11-16)5-3-12/h2-5,11H,6-10H2,1H3

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 109-01-3 1-methyl-piperazine 
• 81172-89-6 terephthalaldehyde mono(diethylacetal) 
• 17201-43-3 4-cyanobenzyl bromide 
• 945762-01-6 N-methoxy-N-methyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 
• 106261-48-7 4-(4-methylpiperazin-1-ylmethyl)benzoic acid 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 26496-94-6 Ethyl 4-(bromomethyl)benzoate 
• 1044872-32-3 4-(4-methyl piperazin-1-ylmethyl)-benzoic acid ethyl ester 
• 622381-65-1 (4-(4-methyl piperazin-1-ylmethyl)phenyl)-methanol 
• 125743-63-7 4-[(4-methyl-1-piperazinyl)methyl]benzonitrile 
• 623-27-8 terephthalaldehyde, 

Downstream Products

• 1044871-87-5 5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one 
• 1246936-00-4 6-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-fulvene 
• 1177252-06-0 1-[(1-benzyl-1H-tetrazol-5-yl){4-[(4-methylpiperazin-1-yl)methyl]phenyl}methyl]-cyclobutyl-1,4-diazepane 
• 1366232-97-4 C₂₇H₃₁N₅O 
• 933986-40-4 1-(4-ethynylbenzyl)-4-methylpiperazine 
• 1346617-86-4 N-[2-methyl-5-(4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-1,2,3-triazol-1-yl)phenyl]-4-(pyridine-3-yl)pyrimidin-2-amine 

Relevant articles and documents

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib

Three novel series of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib were prepared and evaluated in vitro for their cytostatic effects against a human chronic myeloid leukemia (K562), acute myeloid leukemia (HL60), and human leukemia stem-like cell line (KG1a). The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analog. Benzene and piperazine rings were necessary groups in these compounds for maintaining inhibitory activities against the K562 and HL60 cell lines. Introducing a trifluoromethyl group significantly enhanced the potency of the compounds against these two cell lines. Surprisingly, some compounds showed significant inhibitory activities against KG1a cells without inhibiting common leukemia cell lines (K562 and HL60). These findings suggest that these compounds are able to inhibit leukemia stem-like cells.